BAM
RLMD icon

Belpointe Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Belpointe Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000
Closed -$2.26K – 2760
2023
Q1 		$2.26K Hold
1,000
– – ﹤0.01% 3277
2022
Q4 		$3.49K Buy
+1,000
New +$8.78K ﹤0.01% 3060

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Belpointe Asset Management's RLMD Position: Q2 2023 in Review

Belpointe Asset Management sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 1,000 shares — an estimated $2.26K sold.

Belpointe Asset Management first reported a position in RLMD in Q4 2022 and held it in 2 quarters. The position peaked at $3.49K in Q4 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

  • Belpointe Asset Management reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,000 Relmada Therapeutics shares in Q2 2023, an estimated $2.26K.
  • Belpointe Asset Management first reported a position in Relmada Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Relmada Therapeutics position peaked at $3.49K in Q4 2022.
  • 95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.